In summary, this study provides novel insight into a clinically applicable panel consisting of MIR29, LOX, LOXL2, and VEGFA and demonstrates an anti-HCC effect of MIR29A via comprehensively suppressing the expression of LOX, LOXL2, and VEGFA, paving the way to a prospective theragnostic approach for HCC. The gene discussed is LOXL2; the disease is hepatocellular carcinoma.